|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||N/A|
Novartis (NVS) has undergone various changes through acquisitions and divestments over the past two years.
GlaxoSmithKline’s (GSK) HIV business is managed by ViiV Healthcare, a global specialist company in HIV medicines.
On April 27, 2017, Novartis was trading at a forward PE multiple of ~15.8x. The industry currently trades at a forward PE multiple of ~15.9x.